Antibacterial and Phagocytic Properties of a Novel Silver-Interferon Complex
| Parent link: | Anti-Infective Agents Vol. 20, iss. 4.— 2022.— [P. 11-15] |
|---|---|
| Autor principal: | |
| Autor Corporativo: | |
| Otros Autores: | |
| Sumario: | Title screen Background: Developing new antibacterial and antiviral drugs are considered a significant issue due to the emergence and spread of resistant strains of microorganisms. The COVID-19 pandemic has dramatically increased the need for new broad-spectrum anti-infective agents. Objective: This experimental study aimed to investigate the antibacterial and phagocytic properties of silver-interferon preparation. The combination of properties of complex drugs makes them promising for treating drug-resistant infections and bacterial complications of viral diseases. Methods: The antibacterial effect of the silver-interferon platform was investigated by agar diffusion and serial dilution methods. The drug's effect on the functional activity of phagocytes was studied on human neutrophils in a Staphylococcus aureus uptake test. Results: Investigations have shown that the silver-interferon complex possesses a bactericidal mechanism of action against tested bacterial strains, including Streptococcus pneumonia, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli. Streptococcus pneumonia was the most susceptible bacterial target for the tested complex, with a growth inhibition zone of 12±0.6 mm and a minimal bactericidal concentration of 0.08 mg/ml. A slight stimulating action of the drug in relation to the activity of phagocytes was revealed. Conclusion: Silver-interferon has proved as a prospective anti-infective drug with a wide range of activities. [References: 27 tit.] Режим доступа: по договору с организацией-держателем ресурса |
| Lenguaje: | inglés |
| Publicado: |
2022
|
| Materias: | |
| Acceso en línea: | https://doi.org/10.2174/2211352520666220404143923 |
| Formato: | Electrónico Capítulo de libro |
| KOHA link: | https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=668451 |
MARC
| LEADER | 00000naa0a2200000 4500 | ||
|---|---|---|---|
| 001 | 668451 | ||
| 005 | 20250307142235.0 | ||
| 035 | |a (RuTPU)RU\TPU\network\39676 | ||
| 035 | |a RU\TPU\network\34148 | ||
| 090 | |a 668451 | ||
| 100 | |a 20221205d2022 k||y0rusy50 ba | ||
| 101 | 0 | |a eng | |
| 102 | |a AE | ||
| 135 | |a drcn ---uucaa | ||
| 181 | 0 | |a i | |
| 182 | 0 | |a b | |
| 200 | 1 | |a Antibacterial and Phagocytic Properties of a Novel Silver-Interferon Complex |f E. V. Plotnikov, V. M. Plotnikov | |
| 203 | |a Text |c electronic | ||
| 300 | |a Title screen | ||
| 330 | |a Background: Developing new antibacterial and antiviral drugs are considered a significant issue due to the emergence and spread of resistant strains of microorganisms. The COVID-19 pandemic has dramatically increased the need for new broad-spectrum anti-infective agents. Objective: This experimental study aimed to investigate the antibacterial and phagocytic properties of silver-interferon preparation. The combination of properties of complex drugs makes them promising for treating drug-resistant infections and bacterial complications of viral diseases. Methods: The antibacterial effect of the silver-interferon platform was investigated by agar diffusion and serial dilution methods. The drug's effect on the functional activity of phagocytes was studied on human neutrophils in a Staphylococcus aureus uptake test. Results: Investigations have shown that the silver-interferon complex possesses a bactericidal mechanism of action against tested bacterial strains, including Streptococcus pneumonia, Salmonella enteritidis, Staphylococcus aureus, Escherichia coli. Streptococcus pneumonia was the most susceptible bacterial target for the tested complex, with a growth inhibition zone of 12±0.6 mm and a minimal bactericidal concentration of 0.08 mg/ml. A slight stimulating action of the drug in relation to the activity of phagocytes was revealed. Conclusion: Silver-interferon has proved as a prospective anti-infective drug with a wide range of activities. | ||
| 330 | |a [References: 27 tit.] | ||
| 333 | |a Режим доступа: по договору с организацией-держателем ресурса | ||
| 461 | |t Anti-Infective Agents | ||
| 463 | |t Vol. 20, iss. 4 |v [P. 11-15] |d 2022 | ||
| 610 | 1 | |a электронный ресурс | |
| 610 | 1 | |a труды учёных ТПУ | |
| 610 | 1 | |a silver | |
| 610 | 1 | |a antibacterial activity | |
| 610 | 1 | |a immune-stimulation | |
| 610 | 1 | |a interferon | |
| 610 | 1 | |a nosocomial infections | |
| 610 | 1 | |a phagocytosis | |
| 610 | 1 | |a антибактериальная активность | |
| 610 | 1 | |a интерфероны | |
| 610 | 1 | |a фагоцитоз | |
| 700 | 1 | |a Plotnikov |b E. V. |c chemist |c Associate Professor of Tomsk Polytechnic University, Candidate of Chemical Sciences |f 1983- |g Evgeny Vladimirovich |3 (RuTPU)RU\TPU\pers\32469 |9 16417 | |
| 701 | 1 | |a Plotnikov |b V. M. |g Vladimir Mikhaylovich | |
| 712 | 0 | 2 | |a Национальный исследовательский Томский политехнический университет |b Исследовательская школа химических и биомедицинских технологий |c (2017- ) |3 (RuTPU)RU\TPU\col\23537 |
| 801 | 0 | |a RU |b 63413507 |c 20221205 |g RCR | |
| 856 | 4 | |u https://doi.org/10.2174/2211352520666220404143923 | |
| 942 | |c CF | ||